B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies

Leukemia

Volumn 28, Issue 5, 2014, Pages 1163-1167

  Bojarczuk, K ^a   Siernicka, M ^a   Dwojak, M ^a   Bobrowicz, M ^a   Pyrzynska, B ^a   Gaj, P ^a   Karp, M ^b   Giannopoulos, K ^b   Efremov, D G ^c   Fauriat, C ^d   Golab, J ^a,e   Winiarska, M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d INSTITUT PAOLI CALMETTES   (France)

^e INSTITUTE OF PHYSICAL CHEMISTRY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AVL 292; B LYMPHOCYTE RECEPTOR; CC 292; CD20 ANTIBODY; FOSTAMATINIB; IBRUTINIB; IDELALISIB; MONOCLONAL ANTIBODY; OFATUMUMAB; ONO 4059; RITUXIMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BURKITT LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; LETTER; MANTLE CELL LYMPHOMA; MONOTHERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, B-CELL;

EID: 84899929102     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.12     Document Type: Letter

References (13)

1. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
2. Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M. et al. Chronic lymphocytic leukaemia is driven by antigen-independent cellautonomous signalling. Nature 2012; 489: 309-312.
3. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S. et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009; 23: 686-697.
4. Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T. et al. Spleen tyrosine kinase inhibition prevents chemokine-And integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115: 4497-4506.
5. Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013; 27: 1769-1773.
6. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
7. Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M. et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2013; e-pub ahead of print 25 November 2013; doi:10.1038/leu.2013.358.
8. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ. et al. The phosphoinositide 30-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612.
9. Kharfan-Dabaja MA, Wierda WG, Cooper LJN. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 2013; e-pub ahead of print 25 October 2013; doi:10.1038/leu.2013.311.
10. Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed) 2011; 16: 277-306.
11. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM. et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-2088.
12. Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D. et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013; 23: 826-838.
13. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139: 573-586.